Opportunities for APLT Investors to Lead Class Action Lawsuit Against Applied Therapeutics

APLT Investor Notice: Take Action Against Applied Therapeutics

Introduction

Investors who purchased securities of Applied Therapeutics, Inc. (NASDAQ: APLT) between January 3, 2024, and December 2, 2024, are facing significant losses due to unforeseen circumstances surrounding the company's clinical practices. A lead plaintiff is being sought for a class action lawsuit led by Robbins Geller Rudman & Dowd LLP. This article will explore the details of this opportunity, potential implications for investors, and how to get involved.

Background on Applied Therapeutics

Applied Therapeutics is known for developing drug candidates aimed at treating rare diseases. However, complications arose concerning their New Drug Application (NDA) submitted for govorestat, intended for Classic Galactosemia. On January 3, 2024, the company reported its submission to the FDA, but the situation quickly took a turn as outlined in the class action allegations.

Class Action Allegations

The class action lawsuit alleges that the executives at Applied Therapeutics made misleading statements and failed to uphold proper trial protocols. Consequently, these actions led to a significant risk of the FDA rejecting the NDA. The situation deteriorated when a Complete Response Letter was issued by the FDA on November 27, 2024, indicating that the NDA could not be approved in its current state due to deficiencies in the clinical application. The impact was immediate, with APLT stock suffering an over 80% decline in value over three trading sessions following this news.

On December 2, 2024, further revelations from the company regarding FDA warnings about issues with electronic data capture and dosing errors in the study resulted in an additional plummet of over 26% in stock prices. These incidents have contributed to the basis for the class action lawsuit, as shareholders seek accountability from the company and its executives.

How to Get Involved

If you have incurred financial losses due to your investment in Applied Therapeutics during the class period, you can become a lead plaintiff. According to the Private Securities Litigation Reform Act of 1995, any affected investor can step forward. The lead plaintiff is typically the person with the most significant financial interest in the relief sought and is representative of other investors in the class.

Steps to Apply

1. Fill in your information on the designated website for the application of lead plaintiff status.
2. Alternatively, contact Robbins Geller Rudman & Dowd LLP directly at 800/449-4900 or via email at [email protected].

About Robbins Geller Rudman & Dowd LLP

Robbins Geller is a prominent law firm specializing in representing investors in securities fraud cases. With a robust track record of success, the firm has recovered substantial monetary relief for investors and has a team of 200 lawyers across multiple offices. Their expertise could play a crucial role in the potential litigation against Applied Therapeutics.

Conclusion

For investors affected by the events surrounding APLT, the opportunity to lead the class action lawsuit presents a way to seek accountability and potential recovery from losses incurred. The deadline for the appointment of lead plaintiff is February 18, 2025. Investors are encouraged to take action promptly to safeguard their interests and recover losses.

To learn more about the case and your rights as an investor, visit Robbins Geller’s official website.